La cadena de opciones muestra datos clave de las opciones de acciones de AtriCure a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para AtriCure..

AtriCure (NASDAQ:ATRC) Bolsa, Cadena de Opciones

AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

AtriCure Inc

News

Offerings

ATRC

Atricure Files For Mixed Shelf; Size Not Disclosed

WIIM

AtriCure shares are trading lower. The company reported Q4 financial results.

Oppenheimer analyst Suraj Kalia maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Outperform and raises the price target from $36 to $45.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to $45

Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and raises the price target from $40 to $50.

Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $50

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Market Outperform and maintains $60 price target.

Reiteration

JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target

Stifel analyst Rick Wise maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $36 to $48.

Stifel Maintains Buy on AtriCure, Raises Price Target to $48

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $51 price target.

Needham Reiterates Buy on AtriCure, Maintains $51 Price Target

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $61 to $66.

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $66

Earnings

Earnings Beats

Guidance

AtriCure Sees FY25 Adj. EPS ($0.57)-($0.64); Revenue $517M-$527M.

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.23) by 65.22 percent. This is a 61.9 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $124.300 million which beat the analyst consensus estimate of $121.842 million by 2.02 percent. This is a 16.67 percent increase over sales of $106.543 million the same period last year.

AtriCure Q4 2024 Adj. EPS $(0.08) Beats $(0.23) Estimate, Sales $124.300M Beat $121.842M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and raises the price target from $40 to $51.

JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $51

Ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.4, a high estimate of $61.00, and a low estimate of $40.00. Witnessing a positive shift, the current average has risen by 4.46% from the previous average price target of $48.25.
<img src="https://www.benzinga.com/files/images/story/2025/1739214046_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AtriCure's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into AtriCure's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
<h2>About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>A Deep Dive into AtriCure's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.69% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AtriCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.3%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AtriCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.17.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: AtriCure Through The Eyes Of 5 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities raised the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $1,000 to $1,175. B of A Securities analyst Jessica Reif Ehrlich maintained a Buy rating. Netflix shares closed at $869.68 on Tuesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) price target from $162 to $165. JP Morgan analyst Stephen Tusa maintained an Overweight rating. 3M shares closed at $146.89 on Tuesday. <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised the price target for Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) from $129 to $134. Morgan Stanley analyst Erik Woodring maintained an Overweight rating. Seagate shares closed at $101.25 on Tuesday. <a href="https://www.benzinga.com/quote/STX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut the price target for Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from $22 to $15. Jefferies analyst Julien Dumoulin-Smith downgraded the stock from Buy to Hold. Fluence Energy shares closed at $14.41 on Tuesday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Cibus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) price target from $20 to $18. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Cibus shares settled at $2.34 on Tuesday. <a href="https://www.benzinga.com/quote/CBUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) price target from $89 to $93. Wells Fargo analyst Michael Brown upgraded the stock from Equal-Weight to Overweight. Charles Schwab shares closed at $80.93 on Tuesday. <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $40 to $51. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $39.63 on Tuesday.  <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised the price target for Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) from $255 to $280. Loop Capital analyst Chris Dankert upgraded the stock from Hold to Buy. Nordson shares settled at $220.18 on Tuesday. <a href="https://www.benzinga.com/quote/NDSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $184 to $183. Barclays analyst Tim Long maintained an Underweight rating. Apple shares closed at $222.64 on Tuesday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. increased Avino Silver &amp; Gold Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASM#NYSE">ASM</a>) price target from $1.8 to $1.9. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Avino Silver &amp; Gold Mines shares closed at $1.14 on Tuesday. <a href="https://www.benzinga.com/quote/ASM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

AAPL

CBUS

FLNC

NDSN

NFLX

SCHW

Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday

Across the recent three months, 9 analysts have shared their insights on AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.56, a high estimate of $61.00, and a low estimate of $36.00. This current average has increased by 13.91% from the previous average price target of $39.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1737547214_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of AtriCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AtriCure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AtriCure's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>AtriCure's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AtriCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.3%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AtriCure's debt-to-equity ratio is below the industry average at 0.17, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings)

Needham analyst Mike Matson maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $40 to $51.

Needham Maintains Buy on AtriCure, Raises Price Target to $51

Atricure shares are trading higher after announced a year-over-year increase in preliminary Q4 and FY24 revenue results.

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and maintains $40 price target.

Needham Reiterates Buy on AtriCure, Maintains $40 Price Target

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54176794&amp;newsitemid=20250113069942&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=af576ba288c3374b5fcb740b726ff649">AtriCure, Inc.</a> <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54176794&amp;newsitemid=20250113069942&amp;lan=en-US&amp;anchor=%28Nasdaq%3A+ATRC%29&amp;index=2&amp;md5=46444f2ac51f409c3e0a388912e6aeaf">(NASDAQ:</a><a href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst &amp; Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025.
Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over the fourth quarter of 2023. U.S. revenue is expected to be $101.6 million, reflecting growth of approximately 14%, and international revenue is expected to be $22.7 million, an increase of approximately 28% as reported and on a constant currency basis. Fourth quarter revenue was driven by strong growth in our cryoSPHERE&#xAE; devices for pain management, AtriClip&#xAE; devices in open chest procedures, and the EnCompass&#xAE; clamp.
Preliminary, unaudited revenue for full year 2024 is expected to be $465.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over full year 2023. As previously communicated, management expects full year 2024 positive adjusted EBITDA of approximately $26 million to $29 million, and full year 2024 adjusted loss per share of approximately $0.74 to $0.80. Adjusted EBITDA, adjusted loss per share and constant currency revenue growth are non-GAAP measures. AtriCure will provide a reconciliation of non-GAAP measures to the related GAAP measure in the release of audited 2024 results. Management will discuss financial results on the fourth quarter and full year 2024 conference call in February.

Biotech

General

AtriCure Announces Q4 2024 Preliminary Revenue Of $124.3M, Up 17%, And FY Revenue Of $465.3M, U.S. Revenue Up 14% To $101.6M, International Revenue Increased 28% To $22.7M; Forecasted 2024 Adjusted EBITDA Is $26M-$29M And Adjusted Loss Per Share Is $0.74-$0.80

Press Releases

AtriCure to Announce Third Quarter 2024 Financial Results

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure Reports Third Quarter 2024 Financial Results

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

Comments

AtriCure

AtriCure (ATRC) Opciones

AtriCure (NASDAQ:ATRC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL